Liquidia Corporation - Common Stock (LQDA)

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.

Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics

The company’s proprietary dry-powder formulation, supported by Phase 3 data, is viewed as a promising alternative to United Therapeutics’ Tyvaso, though legal challenges remain pending.